WO2004043353A3 - Compositions and methods for treating acute myeloid leukemia - Google Patents

Compositions and methods for treating acute myeloid leukemia Download PDF

Info

Publication number
WO2004043353A3
WO2004043353A3 PCT/US2003/034893 US0334893W WO2004043353A3 WO 2004043353 A3 WO2004043353 A3 WO 2004043353A3 US 0334893 W US0334893 W US 0334893W WO 2004043353 A3 WO2004043353 A3 WO 2004043353A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
myeloid leukemia
acute myeloid
treating acute
methods
Prior art date
Application number
PCT/US2003/034893
Other languages
French (fr)
Other versions
WO2004043353A2 (en
Inventor
Graham J Lieschke
Original Assignee
Ludwig Inst Cancer Res
Graham J Lieschke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Graham J Lieschke filed Critical Ludwig Inst Cancer Res
Priority to AU2003301905A priority Critical patent/AU2003301905A1/en
Publication of WO2004043353A2 publication Critical patent/WO2004043353A2/en
Publication of WO2004043353A3 publication Critical patent/WO2004043353A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of treating acute myeloid leukemia in a mammal in need of such treatment by inhibiting G-CSF activity or reducing G-CSF protein level in the mammal. This may be accomplished, for example, by administering to the mammal an effective amount of an G-CSF antagonist or by inhibiting expression of a G-CSF gene. Compositions and polynucleotide constructs useful in the invention are also disclosed.
PCT/US2003/034893 2002-11-06 2003-11-05 Compositions and methods for treating acute myeloid leukemia WO2004043353A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003301905A AU2003301905A1 (en) 2002-11-06 2003-11-05 Compositions and methods for treating acute myeloid leukemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42401702P 2002-11-06 2002-11-06
US60/424,017 2002-11-06

Publications (2)

Publication Number Publication Date
WO2004043353A2 WO2004043353A2 (en) 2004-05-27
WO2004043353A3 true WO2004043353A3 (en) 2004-11-18

Family

ID=32312737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/034893 WO2004043353A2 (en) 2002-11-06 2003-11-05 Compositions and methods for treating acute myeloid leukemia

Country Status (2)

Country Link
AU (1) AU2003301905A1 (en)
WO (1) WO2004043353A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014150252A1 (en) * 2013-03-15 2014-09-25 Ligand Pharmaceuticals Incorporated Methods of treatment associated with the granulocyte colony-stimulating factor receptor
WO2018102457A1 (en) * 2016-11-30 2018-06-07 Ray Partha S Diagnosis, prognosis and treatment of acute myeloid leukemia
US20230159631A1 (en) * 2017-02-07 2023-05-25 Me Therapeutics Inc. Anti-g-csf antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013886A1 (en) * 1997-09-17 1999-03-25 East Carolina University Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications
US5902584A (en) * 1994-02-08 1999-05-11 Ludwig Institute For Cancer Research Antibodies which bind the G-CSF receptor extracelluar domain and methods of treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902584A (en) * 1994-02-08 1999-05-11 Ludwig Institute For Cancer Research Antibodies which bind the G-CSF receptor extracelluar domain and methods of treatment
WO1999013886A1 (en) * 1997-09-17 1999-03-25 East Carolina University Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JANSEN J. ET AL: "Acute promyelocytic leukemia with a PLZF-RARalpha fusion protein", SEMINARS IN HEMATOLOGY, vol. 38, no. 1, January 2001 (2001-01-01), pages 37 - 41, XP002982084 *

Also Published As

Publication number Publication date
AU2003301905A1 (en) 2004-06-03
WO2004043353A2 (en) 2004-05-27
AU2003301905A8 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
WO2004039774A3 (en) Mitotic kinesin inhibitors
WO2003099211A3 (en) Mitotic kinesin inhibitors
WO2003049678A3 (en) Mitotic kinesin inhibitors
WO2003050064A3 (en) Mitotic kinesin inhibitors
WO2003049527A3 (en) Mitotic kinesin inhibitors
WO2003049679A3 (en) Mitotic kinesin inhibitors
WO2003050122A3 (en) Mitotic kinesin inhibitors
WO2003079973A3 (en) Mitotic kinesin inhibitors
IL165624A0 (en) Mitotic kinesin inhibitors
WO2008063382A3 (en) Antagonists of pcsk9
WO2008057457A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
MXPA05009694A (en) Methods of improving skin quality.
WO2003039460A3 (en) Mitotic kinesin inhibitors
WO2004037171A3 (en) Mitotic kinesin inhibitors
WO2005017190A3 (en) Mitotic kinesin inhibitors
WO2006060680A3 (en) Mda-7 protein variants having antiproliferative activity
WO2005018547A3 (en) Mitotic kinesin inhibitors
WO2005000194A3 (en) Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
MXPA05007689A (en) Treatment of diseases with alpha-7 nach receptor full agonists.
WO2005065183A3 (en) Mitotic kinesin inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP